The Disease Activity Index (DAI) serves as a pivotal quantitative tool for evaluating the clinical progression of colitis in C57 mouse models. By integrating parameters such as weight loss, stool consistency, and rectal bleeding, this scoring system offers a non-invasive method to monitor inflammatory severity. Understanding the standardized assessment of DAI is essential for researchers conducting preclinical studies on inflammatory bowel disease.
Technical Overview
The Disease Activity Index (DAI) is a composite scoring system widely utilized in preclinical research to assess the severity of inflammatory bowel disease (IBD), particularly in chemically induced models like Dextran Sulfate Sodium (DSS) colitis. In C57 mouse strains, which are genetically robust and frequently used for transgenic studies, the DAI provides a reliable correlation between clinical symptoms and histopathological changes. The index aggregates three critical clinical parameters into a single numerical score, allowing researchers to track disease kinetics longitudinally without sacrificing the animal. This methodology ensures that therapeutic interventions can be evaluated based on gross physiological improvements.
Testing Samples
Experimental Subjects
The primary sample for DAI assessment is the live C57BL/6 mouse model. These subjects are typically specific pathogen-free (SPF) grade to ensure that gut inflammation is induced solely by the experimental protocol rather than underlying infections. Both male and female mice can be assessed, though they are often grouped separately to account for sex-based hormonal differences in immune response. The standard age for these samples ranges from 6 to 12 weeks, ensuring physiological maturity while maintaining susceptibility to colitis induction.
Biological Materials
While DAI is primarily a clinical observation, the assessment often correlates with subsequent biological samples. These include distal colon tissue for histology and fecal pellets for microbiome analysis or occult blood testing. The fecal sample is a direct component of the DAI scoring process, specifically for evaluating consistency and the presence of blood.
Testing Items
The DAI score is calculated by summing the scores of three distinct parameters, each typically graded on a scale from 0 to 4. The specific items evaluated during the assessment process include:
Weight Loss: This is the most objective parameter. It is calculated as the percentage of weight loss relative to the initial baseline weight recorded before the induction of colitis.
Stool Consistency: This item evaluates the water content and form of the feces. It ranges from well-formed pellets to liquid diarrhea, indicating the degree of intestinal malabsorption and secretion.
Rectal Bleeding: This parameter assesses the presence of hemoglobin in the stool. It ranges from no blood visible to gross rectal bleeding, often confirmed using a guaiac test for occult blood.
Testing Methods
Experimental Preparation
Before assessment begins, C57 mice must be acclimatized to the laboratory environment for at least one week. A baseline weight must be established for each individual mouse. In typical DSS-induced colitis models, DSS is administered in the drinking water to initiate inflammation, triggering the symptoms required for DAI scoring.
Scoring Procedure
Assessment is performed daily, typically at the same time each morning to minimize variability. The researcher handles each mouse to observe behavior, weighs the animal, and inspects the ano-genital region for stool consistency and signs of bleeding.
Scoring Criteria
A standard scoring matrix is applied as follows:
Weight Loss: 0 points for no loss; 1 point for 1-5% loss; 2 points for 5-10% loss; 3 points for 10-20% loss; and 4 points for over 20% loss.
Stool Consistency: 0 points for normal, well-formed pellets; 2 points for pasty or semi-formed stools; 4 points for liquid diarrhea.
Bleeding: 0 points for no blood; 2 points for occult blood positivity; 4 points for gross rectal bleeding.
The final DAI score ranges from 0 (healthy) to 10 or 12 (severe disease), depending on the specific scaling method used. A higher score indicates more acute inflammation and mucosal damage.
Applications
The DAI assessment in C57 mice is fundamental to various areas of biomedical research. Its primary applications include:
Drug Efficacy Screening: Researchers use DAI to determine if novel anti-inflammatory compounds can reduce the severity of symptoms in colitis models.
Pathogenesis Studies: By correlating DAI scores with histological damage, scientists can understand the temporal progression of IBD.
Genetic Research: C57 mice are the preferred background for transgenic models. DAI allows researchers to compare the susceptibility of knockout or knock-in mice to colitis.
Microbiome Interaction: The index helps link changes in gut flora to clinical outcomes, supporting studies on probiotics and prebiotics.
FAQ
Why is the C57BL/6 strain specifically used for DAI assessment?
The C57BL/6 strain is the most widely used inbred strain for genetic modification and is highly susceptible to DSS-induced colitis. Their genetic uniformity ensures reproducible DAI results across different laboratories.
How often should DAI be assessed?
For acute colitis models, DAI is typically assessed daily. In chronic models, the frequency may be reduced, but daily monitoring provides the most accurate disease kinetic curve.
Is DAI sufficient to prove therapeutic effect?
While DAI is a strong clinical indicator, it is not sufficient on its own. It must be corroborated with histological analysis of colon length and tissue damage, as well as molecular markers of inflammation, to provide a comprehensive evaluation.